Abstract: ObjectiveTo analyze the clinical characteristics and prognosis of patients with breast cancer brain metastases in different subtypes. MethodsRetrospective clinical and survival analyses were performed in 90 breast cancer patients with brain metastases. Patients were divided into estrogen receptor (ER) + and/or progesterone receptor (PR) +, human epidermal growth receptor-2 (HER-2) +, and triple negative (ER-,PR- and HER-2-) subtypes. ResultsIn the 90 patients, there were 51 patients(56.7%) with ER+ and/or PR+12 patients(13.3%) with HER-2+ and 27 patients(30%) with triple negative breast cancer. The median DFS (disease free survival ) was 30.9，25.4 and 16.0 months (P=0.001)among ER+ and(or)PR+，HER-2+ and triple negative breast cancer . The median brain disease free survival was 36.0 ，38.0 and 22.0 months (P=0.008)among the above three types. The median OS (overall survival) was 52.0，25.5 and 36.6 months (P=0.075)among the three types. The median survival from brain metastasis was 11.0，5.5 and 8.0 months (P=0.829) among the three types. Conclusion The triple negative subtype was more prone to metastasize to brain with a shorter median disease free survival compared with other two subtypes. The median overall survival and survival from brain metastasis were similar among three subtypes.